Efek Aktivasi Jalur Apoptosis Sel T pada Derajat Keparahan Pasien dengan COVID-19
Abstract
Pendahuluan: Sel T merupakan salah satu jenis sel imunitas yang memiliki peran vital pada perlawanan tubuh terhadap penyakit infeksi yang salah satunya adalah COVID-19. Sehingga terjadinya apoptosis sel T diduga merupakan salah satu indikator yang disinyalir sangat penting dalam perjalanan progresitivitas penyakit COVID-19 menjadi lebih berat. Tujuan: Mengetahui efek apoptosis sel T pada derajat keparahan pasien dengan COVID-19. Metode: Jurnal dipilih dari database online yang sudah dipulikasi pada sciencedirect, proquest, pubmed, springer, dan google scholar dengan kriteria inklusi jurnal akses terbuka, berbahasa inggris, dan indikator apoptosis sel T yang valid. Artikel yang direview akan dianalisis menggunakan diagram alur PRISMA. Hasil: Dari tujuh jurnal yang sudah dilakukan sistematik review menunjukkan bahwa terdapat hubungan antara tingginya nilai indikator apoptosis sel T dengan tingginya derajat keparahan pasien dengan COVID-19. Simpulan: Apoptosis sel T terbukti sangat mempengaruhi derajat keparahan pasien dengan penyakit COVID-19 sehingga jalur yang mengintervensi aktivasi apoptosis sel T dapat menjadi pilihan untuk mencegah progresitivitas penyakit COVID-19 menjadi lebih buruk.
Full Text:
PDFReferences
BERTHE F. The global economic impact of ASF. Bull l’OIE. 2020;2020(1):1–2.
WHO. Public Health Surveillance for COVID-19. Interim Guid [Internet]. 2022;(February):253–78. Available from: https://www.who.int/publications/i/item/who-2019-nCoV-surveillanceguidance-2020.8
Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Clinical Features of COVID-19 and Factors Associated with Severe Clinical Course: A Systematic Review and Meta-Analysis. SSRN Electron J. 2020.
Or Caspi, Michael J. Smart RBN. COVID-19: Staging of a New Disease. Ann Oncol. 2020;(January):19–21.
Aguilar RB, Hardigan P, Mayi B, Sider D, Piotrkowski J, Mehta JP, et al. Current Understanding of COVID-19 Clinical Course and Investigational Treatments. Front Med. 2020;7(October).
Burke R, Midgley C, Dratch A, Fenstersheib M, Haupt T, Holshue M. Novel Coronavirus: Current Understanding of Clinical Features, Diagnosis, Pathogenesis, and Treatment Options. MMWR Morb Mortal Wkly Rep. 2020;69:245e6.
Kooshkaki O, Derakhshani A, Conradie AM, Hemmat N, Barreto SG, Baghbanzadeh A, et al. Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. Front Oncol. 2020;10(October):1–17.
Tu H, Tu S, Gao S, Shao A, Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. 2020;(January).
Shimizu Y. Immunopathogenesis and therapy of COVID-19. Ars Curandi Odontol. 2020;1(5):46–8.
Cilloniz C, Martin-Loeches I, Garcia-Vidal C, Jose AS, Torres A. Microbial etiology of pneumonia: Epidemiology, diagnosis and resistance patterns. Int J Mol Sci. 2016;17(12).
D’Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, et al. CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest. 2009;119(10):2898–913.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9.
Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, et al. Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. Immunity [Internet]. 2020;53(2):442-455.e4. Available from: https://doi.org/10.1016/j.immuni.2020.06.024.
Bergamaschi L, Mescia F, Turner L, Hanson AL, Kotagiri P, Dunmore BJ, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54(6):1257-1275.e8.
Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10):1–11.
Liu Y, Garron TM, Chang Q, Su Z, Zhou C, Qiu Y, et al. Cell-type apoptosis in lung during sars-cov-2 infection. Pathogens. 2021;10(5).
Wu DD, Pan PH, Liu B, Su XL, Zhang LM, Tan HY, et al. Inhibition of alveolar macrophage pyroptosis reduces lipopolysaccharide-induced acute lung injury in mice. Chin Med J (Engl). 2015 Jan 10;128(19):2638–45.
Ramirez MLG, Salvesen GS. A primer on caspase mechanisms. Vol. 82, Seminars in Cell and Developmental Biology. Elsevier Ltd; 2018. p. 79–85.
Sangiuliano B, Pérez NM, Moreira DF, Belizário JE. Cell death-associated molecular-pattern molecules: Inflammatory signaling and control. Vol. 2014, Mediators of Inflammation. Hindawi Publishing Corporation; 2014.
Jordan RE, Adab P, Cheng KK. Covid-19: Risk factors for severe disease and death. BMJ [Internet]. 2020;368(March):1–2. Available from: http://dx.doi.org/doi:10.1136/bmj.m1198
André S, Picard M, Cezar R, Roux-Dalvai F, Alleaume-Butaux A, Soundaramourty C, et al. T cell apoptosis characterizes severe Covid-19 disease. Cell Death Differ. 2022;(January):1–14.
Cizmecioglu A, Akay Cizmecioglu H, Goktepe MH, Emsen A, Korkmaz C, Esenkaya Tasbent F, et al. Apoptosis-induced T-cell lymphopenia is related to COVID-19 severity. J Med Virol. 2021;93(5):2867–74.
Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11(May):1–7.
Xu J, Liu Z, Liu H, Luo Y, Kang K, Li X, et al. Decreased t cell levels in critically ill coronavirus patients: Single-center, prospective and observational study. J Inflamm Res. 2021;14:1331–40.
Yang Y, Kuang L, Li L, Wu Y, Zhong B, Huang X. Distinct Mitochondria-Mediated T-Cell Apoptosis Responses in Children and Adults with Coronavirus Disease 2019. J Infect Dis. 2021;224(8):1333–44.
Adamo S, Chevrier S, Cervia C, Zurbuchen Y, Raeber ME, Yang L, et al. Lymphopenia-induced T cell proliferation is a hallmark of severe COVID-19. 2020; Available from: https://doi.org/10.1101/2020.08.04.236521
Adamo S, Chevrier S, Cervia C, Zurbuchen Y, Raeber ME, Yang L, et al. Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. Allergy Eur J Allergy Clin Immunol. 2021;76(9):2866–81.
Zou ZY, Ren D, Chen RL, Yu BJ, Liu Y, Huang JJ, et al. Persistent lymphopenia after diagnosis of COVID-19 predicts acute respiratory distress syndrome: A retrospective cohort study. Eur J Inflamm. 2021;19:1–10.
Liu Y, Tan W, Chen H, Zhu Y, Wan L, Jiang K, et al. Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19. BMC Infect Dis. 2021;21(1):1–10.
Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther [Internet]. 2020;5(1):1–8. Available from: http://dx.doi.org/10.1038/s41392-020-00243-2
Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–93.
Connors TJ, Ravindranath TM, Bickham KL, Gordon CL, Zhang F, Levin B, et al. Airway CD8+ T cells are associated with lung injury during infant viral respiratory tract infection. Am J Respir Cell Mol Biol. 2016;54(6):822–30.
Taghiloo S, Aliyali M, Abedi S, Mehravaran H, Sharifpour A, Zaboli E, et al. Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID-19 patients: Clinical and laboratory characteristics. J Med Virol. 2021;93(3):1589–98.
Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol [Internet]. 2020;17(5):541–3. Available from: http://dx.doi.org/10.1038/s41423-020-0401-3
Liu X, Zhao J, Wang H, Wang W, Su X, Liao X, et al. Metabolic Defects of Peripheral T Cells in COVID-19 Patients. J Immunol. 2021;206(12):2900–8.
